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Liposomes are frequently used as pharmaceutical nanocarriers to deliver poorly water-soluble drugs such as temoporﬁn,
cyclosporine A, amphotericin B, and paclitaxel to their target site. Optimal drug delivery depends on understanding the release
kinetics of the drug molecules from the host liposomes during the journey to the target site and at the target site. Transfer of
drugs in model systems consisting of donor liposomes and acceptor liposomes is known from experimental work to typically
exhibit a ﬁrst-order kinetics with a simple exponential behavior. In some cases, a fast component in the initial transfer is present,
in other cases the transfer is sigmoidal. We present and analyze a theoretical model for the transfer that accounts for two physical
mechanisms, collisions between liposomes and diﬀusion of the drug molecules through the aqueous phase. Starting with the
detailed distribution of drug molecules among the individual liposomes, we specify the conditions that lead to an apparent ﬁrst-
order kinetic behavior. We also discuss possible implications on the transfer kinetics of (1) high drug loading of donor liposomes,
(2) attractive interactions between drug molecules within the liposomes, and (3) slow transfer of drugs between the inner and
outer leaﬂets of the liposomes.
1.Introduction
Poor solubility in water is a well-recognized obstacle for ef-
ﬁcient oral or parenteral drug administration [1, 2]. Lipos-
omes are among the most widely used type of pharmaceu-
tical nanocarriers for small and poorly water-soluble drug
molecules [3]. These drugs preferentially partition into the
hydrophobic compartment that is formed by the hydrocar-
bon tails of the liposomal lipids. Liposomes have been used
in their ﬁrst generation (conventional liposomes) predomi-
nantly as long-circulating transport vehicles [4, 5], followed
by a second generation that improved the circulation time
further by decorating the surface with PEG-chains (stealth
liposomes [6]). Third-generation liposomes are now being
engineered to contain targeting ligands [7]a n dt oc a r r yo u t
stimuli-sensitive triggering of the drug release [8].
An important property of liposome-based drug delivery
is the release kinetics of the drug from the host, which has
been investigated for a number of model systems [9–12].
Experimental investigations of the transfer of temoporﬁn
between two diﬀerent types of liposomes (i.e., from donor
liposomes to acceptor liposomes) have recently been carried
out using a mini ion exchange column technique [13]. The
column separates donor from acceptor liposomes and thus
allows to monitor the time dependence of the drug transfer.
It is observed that, typically, the transfer follows an apparent
ﬁrst-order behavior, characterized by a single exponential
function. This is remarkable given the complexity of the
system, with the drug molecules being able to migrate from
the donor to the acceptor liposomes via diﬀerent physical
mechanisms. In fact, there are two mechanisms that, in
general, act simultaneously. The ﬁrst mechanism is the
transfer of drugs upon collisions between two liposomes.
In this case, the drug molecules directly migrate from one
liposome to another with minimal exposure to the aqueous
phase. The second mechanism refers to the transfer of drugs
via diﬀusion through the aqueous phase. We note that
the collision mechanism has been invoked, for example,
to explain the transfer of lipids [14] and cholesterol [15]
between vesicles, and the transfer of fatty acids between2 Journal of Drug Delivery
vesicles and fatty acid binding proteins [16]. Also the
diﬀusion mechanism was found to be consistent with the
transport of lipids [17]. In some cases, both mechanisms
were suggested to contribute to the transport of lipids
between vesicles [18] and to the transport of lipophilic drugs
from oil-in-water emulsions to cells [19]a n df r o mp l a s m a
proteins to lipid vesicles [20]. In our preceding experimental
work, where we have investigated the kinetics of temoporﬁn
transport from donor to acceptor liposomes [13], we found
that above a certain concentration (corresponding to a
liposome-to-liposome distance of about 200nm for our
speciﬁc system) the transfer was dominated by collisions;
for smaller concentrations transport through diﬀusion was
prevalent.
The objective of the present work is to introduce and
discuss a detailed kinetic model for the release properties
of poorly water-soluble drug molecules from liposomal
nanocarriers. Despitea largenumber ofexperimental studies
about the kinetics of lipid and drug transfer between lipo-
somes and other nanocarriers, there is little theoretical work
available that addresses the nature of the transfer kinetics.
Our theoretical formalism is based on a detailed distribution
function of drug molecules among the individual liposomes.
Kinetic rate equations for that distribution function account
for two transport mechanisms: collisions between liposomes
and drug diﬀusion through the aqueous phase. We specify a
set of conditions at which our microscopic model produces
an apparent ﬁrst-order kinetics with simple exponential
behavior,asusedinpreviouswork[14,19].Wepointoutthat
our kinetic model can be applied to any kind of small mobile
pharmaceutical nanocarrier, including liposomes, micelles
[21], colloids [22], and nanoparticles [23].
In the second part of our work, we discuss conditions
that lead to deviations from simple exponential behavior.
First, for the diﬀusion mechanism, high drug loading tends
toincreasethetransferrate.Thekineticsremainsexponential
only if donor and acceptor liposomes are chemically similar.
Second, the presence of attractive interactions between drug
molecules within the liposomes (which can result in the
formation of aggregates [24]) is expected to slow down
the transfer kinetics. We note that not much molecular
detail is presently known about how poorly water-soluble
drug molecules inside a lipid bilayer interact. However,
modeling studies of rigid membrane-embedded inclusions
such as transmembrane proteins or peptides suggest a
general tendency of the host membrane to mediate attrac-
tive interactions between inclusions that may lead to the
formation of aggregates [25]. These attractive interactions
may be driven by elastic deformations of the host membrane
[26], by depletion of the ﬂexible lipid chains from the
region in between rigid inclusions [27], and by ﬂuctuations
via the Casimir eﬀect [28]. Our analysis for the collision
mechanism suggests that aggregate formation can give rise
to sigmoidal behavior of the transfer kinetics. Third, drug
molecules (even if they are poorly water soluble) do not
necessarily reside predominantly in the innermost region
of the membrane’s hydrocarbon region. For example, some
aromatic compounds such as indole are well known for
theirpreferenceofthemembrane’sinterfacialregionbetween
the headgroups and the hydrocarbon chains [29, 30].
Other aromatic compounds such as benzene are distributed
throughout the hydrocarbon chain region without a bias
toward the polar/apolar interface [30]. Among the reasons
for the preferential partitioning of indole are electrostatic
interactions, hydrogen bond formation, and the steric shape
of the molecule. For lipid monolayers, there is evidence
that drug partitioning also depends on the lateral pressure
[31]. Generally, whenever a drug molecule interacts more
favorably with the interfacial or headgroup region than with
the hydrocarbon tail region, the corresponding partitioning
preference can be lumped into at least two energetically
preferred statesthat correspond to the inner and outerleaﬂet
of the membrane. Transfer between the two states (i.e., ﬂip-
ﬂop) then introduces an additional characteristic time [32].
We note that two- or multiple-state modeling has been
invoked previously to model the partitioning of amino-acid
analogues in membranes [33]a n dt h ep e r m e a t i o no fd r u g
molecules through membranes [34, 35].
2.Model
Consider an aqueous solution (of ﬁxed volume V)t h a t
contains a number of Nd donor and Na acceptor liposomes.
Donor and acceptor liposomes may be either two chemically
diﬀerent types of liposomes (i.e., composed of diﬀerent
lipids) or equivalent liposomes (i.e., containing the same
lipid composition). Inthelattercase, the distinctionbetween
donor and acceptor liposomes refers only to their initial
loading; at the end of the transport process (i.e., at thermal
equilibrium), both types would be indistinguishable.
The donor liposomes initially carry a total number of
M poorly water-soluble drug molecules. Transfer of drug
molecules from donor to acceptor liposomes will take place
with time until, eventually, an equilibrium partitioning is
reached. We describe the time dependence of this transfer
by the number of drug molecules carried by the donor
liposomes, Md(t), and by the acceptor liposomes, Ma(t). It
is then initially Md(t = 0) = M and Ma(t = 0) = 0, as well
as in equilibrium Md(t →∞ ) = M
eq
d and Ma(t →∞ ) =
M
eq




a denote the equilibrium number
of drug molecules carried by donor and acceptor liposomes,
respectively. We point out that, althoughwe refer to the drug
carriers as liposomes, our model is more general. That is,
it can be applied to diﬀerent types of mobile carriers such
as micelles, colloids, nanoparticles, or polymeric aggregates,
given the carrier possesses some capacity to host poorly
water-soluble drug molecules.
In the following, we suggest a model for the time
dependenceofthetransferprocess(i.e.,forMd(t)andMa(t))
that leads to a ﬁrst-order kinetics, characterized by a simple
exponential function. We consider a “single-state model”
where there is only a single energetic state available for
each drug molecule in a given liposome. The single-state
model excludes the presence of intraliposomal kinetics (the
extension to a two-state model will be discussed below). We
account for two diﬀerent transport mechanisms: (i) trans-
port through collisions between liposomes and (ii) transportJournal of Drug Delivery 3
Collision
Diffusion
Figure 1: Transfer of a drug molecule (black bullets) from donor
liposome (dark-shaded) to acceptor liposome (light-shaded) upon
the collision of the two liposomes or upon diﬀusion of the drug
molecule through the aqueous phase. The displayed scheme refers
to the special situation of initially empty acceptor liposomes but
analogous schemes apply to any other initial situation.
via diﬀusion of drug molecules through the aqueous phase.
Both mechanisms are schematically illustrated in Figure 1.
Our transport model of drugs from donor to acceptor
liposomes employs the framework of chemical reaction
kinetics. We note that due to the generally slow release
kinetics of poorly water-soluble drugs, we can treat the
aqueous solution as spatially uniform at all times. Hence,
no combined diﬀusion-reaction kinetics [36] needs to be
included in our model.
2.1. Transfer through Collisions Only. O u rm o d e lf o rt h e
collision-mediated drug transfer between liposomes starts
with the detailed distribution of drug molecules among all
liposomes. We introduce the number dj of donor liposomes
that carry j drug molecules. An analogous deﬁnition is
used for the number aj of acceptor liposomes that carry j
drug molecules. The index j is conﬁned to the region 0 ≤
j ≤ m where m is the maximal number of drug molecules
that a liposome can carry. The time-dependent distribution
functions dj = dj(t)a n daj = aj(t)r e p r e s e n taf u l l
microscopic knowledge of the kinetics of drug transfer. The
total numbers of donor liposomes Nd, acceptor liposomes
Na, drug molecules residing in donor liposomes Md,a n d
drug molecules residing in acceptor liposomes Ma,c a nb e
calculated on the basis of the distribution functions dj =
















Mathematically, Nd and Na are the zeroth-moments of the
distributions functions dj = dj(t)a n daj = aj(t)w h e r e a s
Md and Ma appear as the corresponding ﬁrst moments. We
assume that Nd and Na are constant (i.e., independent of
time), and so then is the total number of liposomes N =
Nd + Na. This is appropriate if fusion and ﬁssion between
liposomes can be ignored. Due to our focus on poorly water-
soluble drug molecules, it is also justiﬁed to assume that the
total number of drug molecules carried by all liposomes,




Figure 2: Exempliﬁcation of our system: Nd = 6 donor liposomes
(dark shaded) and Na = 9 acceptor liposomes (light shaded) reside
in an aqueous space of volume V; each liposome can carry at
most m = 3 drug molecules (black bullets). For the displayed
hypothetical snapshot (taken at a certain time t), the distribution
function of drug molecules among the donor liposomes is d0 = 1,
d1 = 2, d2 = 2, d3 = 1, leading to a total of Md =
m
j=0 jdj = 9
drug molecules residing in donor liposomes. Analogously for the
acceptor liposomes, the distribution function is a0 = 5, a1 = 3,
a2 = 1, a3 = 0, implying Ma =
m
j=0 jaj = 5.
Initial Final
Figure 3: Transfer of a drug molecule (black bullets) upon
the collision of two liposomes (here assumed to be two donor
liposomes). The drug distribution function changes from initially
d1 = 1, d2 = 0, d3 = 0, d4 = 0, d5 = 1t od1 = 0, d2 = 1, d3 = 0,
d4 = 1, d5 = 0. This represents an example (for i = 5a n dj = 1) of
the general scheme di → di −1, di−1 → di−1 +1 ,dj → dj −1, and
dj+1 → dj+1 +1.
fraction of drug molecules that reside in the aqueous phase
without being bound to a liposome. Figure 2 schematically
illustrates a speciﬁc exempliﬁcation of the system.
Collisions require two liposomes to come to close prox-
imity. The magnitude of drug transport between, say, donor
liposomesdi anddj isthus∼ di×dj/V where V isthevolume
of the aqueous solution. The underlying transfer process is
thus second order. If a single drug molecule is transferred
from a donor that carries initially i drug molecules to a
donor that carries initially j drug molecules, the distribution
function changes according to di → di − 1, di−1 → di−1 +1 ,
dj → dj−1, anddj+1 → dj+1+1. Hence,thenumbers di and
dj decrease whereas di−1 and dj+1 increase. Figure 3shows an
illustration of this scheme for i = 5a n dj = 1. The transfer
rate between the populations di and dj will also depend on
the corresponding numbers of drug molecules i and j.W e
assume the drug molecules within each liposome form an
ideal mixture so that the transfer rate is directly proportional4 Journal of Drug Delivery
to |i− j|. In writing a rate equation for donor population dj,
we have to account for all possible ways of collisions between
donor liposomes of index j with other liposomes (donors






























































= i − j. (3)
In (2), Kcoll is theunit rate ofdrug transfer through collisions
betweentwochemicallyequivalentliposomes, and ˙ x = dx/dt
denotes the time derivative of a physical quantity x(t). The
ﬁrsttwolinesin(2)accountforcollisionsofdonorliposomes
with otherdonorliposomes. The last twolinesin (2) account
for collisions of donor liposomes with acceptor liposomes.
Note that (2) allows for a diﬀerence in the chemical
nature of donor and acceptor liposomes. This chemical
mismatch is accounted for by the integer k in the last two
lines of (2), which expresses the diﬀerence in the number
of drug molecules between a donor and acceptor liposomes
in thermal equilibrium, (i.e., for k = 0 each donor and
acceptor liposome will contain the same number of drug
molecules in thermal equilibrium). We do not attempt to
calculate k from a microscopic model; yet below we show
how k is related to the change in standard Gibbs free energy
for the process of transferring drug molecules from donor to
acceptor liposomes.
Duetosymmetry, weobtain ˙ aj from ˙ dj byreplacing di →

























































Equations(2)a n d( 4) constitute a microscopic model for the













˙ aj + ˙ dj
	
= 0, (5)
implying ˙ Nd = ˙ Na = ˙ M = 0 and thus ensuring conservation
of the number of donor and acceptor liposomes (Nd and
Na)a sw e l la so ft h et o t a ln u m b e ro fd r u gm o l e c u l e s( M =
Md + Ma). To characterize the total numbers Md and Ma of
drug molecules that reside in donor and acceptor liposomes,
respectively, we carry out the summations
m
j=0 j ˙ dj and
m









(MdNa − MaNd − kNaNd),
(6)






Initially, all drug molecules are incorporated in the donor
liposomes, implying Md(t = 0) = M and Ma(t = 0) = 0.
The solution of (6)i st h e n





(M − kNd). (8)
Hence, K indeed appears as the inverse characteristic time
for the transfer process. In contrast to previous models [14],
K depends only on the total concentration of liposomes
N/V but not on the concentrations of donor or acceptor
liposomes individually. We also mention that (6)a n dt h e
solution in (8) are valid for any number of donor and
acceptor liposomes (i.e, any choice of Nd and Na). This
includesbutisnot restricted to sink conditions(where Na  
Nd).
Thermodynamic equilibrium corresponds to the long-


































From (9), we obtain the diﬀerence between the num-
bers of drug molecules per donor and acceptor liposome,
(M
eq
d /Nd) − (M
eq
a /Na) = k. This agrees with our interpreta-
tion of k in (2)a n d( 4). We note that for chemically identical
donor and acceptor liposomes, it is k = 0 and all liposomes
carry the same number of drug molecules in equilibrium,
implying M
eq
d /Nd = M
eq
a /Na = M/N. The largest possible
value of k is k = M/Nd for which we obtain M
eq
a = 0a n d
M
eq
d = M. The smallest possible value of k is k =− M/Na
implying M
eq
a = M and M
eq
d = 0. Hence, −M/Na ≤ k ≤
M/Nd.Journal of Drug Delivery 5
The solution in (8) corresponds to a simple exponential
decay of the number of drug molecules in the donor
liposomes. This suggests that we can express the transfer
kinetics of drug molecules from donor (D) to acceptor (A)






with rate constants K1 and K2. The corresponding kinetic
behavior is then governed by the equations ˙ Md =− K1Md +
K2Ma and ˙ Ma = K1Md−K2Ma where Md = Md(t)an dMa =
Ma(t) are the numbers of drug molecules carried by donor
and acceptor liposomes, respectively. With Md(t = 0) = M
and Ma(t = 0) = 0w eo b t a i n












which has indeed the same structure as (8). Comparison of
(8)w i t h( 11)r e v e a l sK1 = (1 − kNd/M)KNa/N and K2 =
(1 + kNa/M)KNd/N. The equilibrium constant Keq = K1/K2







Comparing this with Keq = exp(−Δg0/kBT)( w h e r ekB is
Boltzmann’s constant and T is the absolute temperature)
allows us to compute the change in standard Gibbs free
energy







for the transfer of a single drug molecule from a donor to
an acceptor liposome. The enthalpic and entropic contri-
butions to Δg0 will be inﬂuenced by k,w h i c hi s ,g e n e r a l l y ,
temperature dependent(k = k(t)). Let us brieﬂy discuss two
cases. First, if donor and acceptor liposomes are chemically
identical, then k = 0a n dΔg0 = kBT ln(Nd/Na) has only
an entropic contribution. Speciﬁcally, for Nd >N a,w eﬁ n d
Δg0 > 0 because a given drug molecule has more donor
liposomes to reside in than acceptor liposomes. Second, the
limitingcasesfor k,namely ,k =− M/Na andk = M/Nd,yield
Δg0 →− ∞ (thus, with all drugs migrating to the acceptor
liposomes) and Δg0 →∞(thus with all drugs remaining in
the donor liposomes), respectively.
We point out that our model predicts a simple expo-
nential time behavior despite the presence of drug transfer
through a second-order two-body collision process (i.e.,
collisions between two liposomes). Chemical reactions that
deplete the reactants through binary collisions generally
display a long time-tail c(t) ∼ 1/t in their concentration
dependence. For example, the kinetic behavior of the dimer-
ization reaction 2 monomer → dimer follows the equation
˙ c =  kc2 where c(t) is the concentration of the reactant
(i.e., the monomers) and  k the rate constant. With an initial
concentration c(t = 0) = c0 the time behavior becomes
c(t) = c0/(1 +  kt), implying c(t) ∼ 1/t for long times. For
our system, however, the numbers of donor and acceptor
liposomesremain unchanged.Thus,collisionsdonotdeplete
the reactants, and the concentration dependencies of Md(t)
and Ma(t) become exponential in time.
2.2. Transfer through Diﬀusion Only. Diﬀusion allows for
transfer of drug molecules directly through the aqueous
phase, without the need of collisions between liposomes.
Denoting the additional state in the aqueous phase by W (in
addition to donor (D) and acceptor (A)) the corresponding
transport scheme (again, as in (10), formally expressed as a




















d ,a n dK
upt
a for the drug
release (“rel”) and uptake (“upt”) in donor (“d”) and
acceptor (“a”) liposomes. To formulate the rate equations, it
isusefultoﬁrst considerthedrugdistributionfunctiondj(t).
We assume the probability of a drug molecule to leave donor
liposomes of index j to be proportional to the total number
jdj ofdrugmoleculesinthatliposome population.Similarly,
the probability of a drug molecule to enter donor liposomes
of index j i sa s s u m e dt ob ep r o p o r t i o n a lt ot h et o t a ln u m b e r
(m−j)dj ofemptybindingsitesinthatliposome population.
Because the uptake is based on collisions of liposomes with
drug molecules in the aqueous solution, the rate should
also be proportional to the drug concentration Mw/V in
the aqueous phase (here, Mw is the total number of drug
molecules residing in the aqueous phase). This leads to the
following rate equations

























for 0 ≤ j ≤ m (with dj = aj = 0f o rj<0o rj>m ). A
similar equation can be written for the acceptor liposomes.
Based on (15), it can be veriﬁed that
m
j=0 ˙ dj = 0, thus
ensuring conservation of Nd (and similarly for Na). Carrying
out the summation ˙ Md =
m
j=0 j ˙ dj using (15)l e a d st o
˙ Md =− Krel





(mNd − Md). (16)
This equation simply expresses the proportionality of the
release to the total number of bound drug molecules and
the proportionality of the uptake to the total number of free
bindingsites.Consistentwith(16)w ecompletethesetofrate
equations corresponding to the scheme in (14)
˙ Mw = Krel













˙ Ma =− Krel
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To obtain ﬁrst-order behavior, we make three assumptions.
The ﬁrst is a steady-state approximation for the number
of drug molecules in the aqueous phase, ˙ Mw = 0. The
solubility limit of poorly water-soluble drugs is small so
that, eﬀectively, any release of drugs from one liposome is
accompanied by an immediate uptake by another (or the
same [38]) liposome. The second assumption is weak drug
loading of all liposomes; this amounts to Md   mNd,
Ma   mNa,a n dM   mN. We ﬁnally assume the same
ratefortheuptakeofdrugmoleculesfromtheaqueousphase





This is strictly valid only for chemically equivalent donor
and acceptor liposomes but should generally be a reasonable
approximation. That is, we expect the energy barrier for
entering a liposome from the aqueous phase to be small
(as compared to the energy barrier for the release from a
liposome), irrespective of the liposome’s chemical structure.
Subject to our three assumptions (16)a n d( 17)b e c o m e
equivalent to



















Equation (18) are now identical to (6)i fw ei d e n t i f yKrel
d =
Kdiﬀ (1−(kNd)/M)andKrel
a = Kdiﬀ(1+kNa/M)whereKdiﬀ =
K appears as the rate constant. Here again, as for (6), the
validity of (18) is not subject to a restriction with respect to
Nd and Na.
3.Discussion
Both transfer mechanisms, through liposome collisions and
via diﬀusion through the aqueous phase, lead to the same
ﬁrst-order kinetic behavior; see (6)a n d( 18). The rate





Its dependence on the total liposome concentration allows
the experimental determination of the transfer mechanism
[13]. We note that the ﬁrst-order behavior predicted by (6)
and (18) requires several assumptions to be fulﬁlled: low




change if any of these assumptions is not fulﬁlled.
3.1. Extension to High Drug Loading. While high drug
loading obviously increases the number of available drug
molecules (and thus increases the eﬃciency of liposomal
carriers [39]) it also aﬀects the kinetics of the drug release.
Our present model predicts such a dependence for the
diﬀusion mechanism whereas the kinetics for the collision
mechanism is not aﬀected. Recall that the transition from
(16)a n d( 17)t o( 18) was based on the approximation of
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Figure 4: Numerical solutions of (20), derived for M/(Nm) = 0
(broken lines) and M/(Nm) = 0.5 (solid lines). The remaining
parameters are Krel
d /Krel
a = 3, Nd/N = Na/N = 0.5. The time t is
plotted in units of 1/Krel
a .
weak drug loading, Md   mNd, Ma   mNa,a n dM   mN.
Without that approximation, we obtain instead of (18)a
nonlinear set of diﬀerential equations





















For the special case that donor and acceptor liposomes are
chemically similar, Krel
d = Krel
a = Kdiﬀ,w eo b t a i nas i m p l e
exponential behavior
Ma(t) = M − Md(t) =





Here, high drug loading simply increases the rate constant
for the diﬀusion mechanism by the factor 1/(1 − M/(mN)).
In the general case Krel
d / =Krel
a , and no simple exponential
decay is predicted for high loading of the liposomes with
drug molecules. Figure 4 shows a numerical example, based
on (20)w i t hKrel
d /Krel
a = 3a n dNd/N = Na/N = 0.5. For
M   mN (weak loading regime; broken lines in Figure 4)
we observe the simple exponential behavior according to
(18) with equilibrium values M
eq
d /M = 1/4a n dM
eq
a /M =
3/4. For M/(mN) = 0.5 the initial loading of the donor
liposomes is maximal. This leads to both a faster decay and





3 − 1)/2 = 0.366 and M
eq
a /M = (3 −
√
3)/2 = 0.634. The
reason fortheincreased rate constantis thereducedabilityof
highly loaded liposomes to take up drug molecules. Hence,
if drug molecules are released from initially highly loadedJournal of Drug Delivery 7
donorliposomestheywill betakenupexclusivelybyacceptor
liposomes. The increase in the transfer rate at high loading
also aﬀects the equilibrium values M
eq
d /M and M
eq
a /M.T h e
equilibriumis shifted toward a more uniform distribution of
drug molecules between donor and acceptor liposomes (in
agreement with Figure 4).
3.2. Sigmoidal Behavior. Our model presented so far is
unable to predict sigmoidal behavior. That is, no inﬂection
point can be observed in Md(t)a n dMa(t). Behind this
prediction is our assumption that the transfer rates are
strictly proportional to the concentration diﬀerence of
the drug molecules. For the collision mechanism, this is
expressed by our deﬁnition of the function g(i, j)i n( 3).
However, if drug molecules within a given liposome interact
with each other, the simple relation g(i, j) = i − j will
no longer be valid. More speciﬁcally, attractive interactions
between drug molecules within liposomes will increase the
energy barrier to remove a drug molecule. This becomes
relevant at high drug loading. Hence, in the presence of
attractive interactions, it will be more unlikely that a drug
molecule is transferred from a highly loaded donorliposome
to an empty acceptor liposome.
We discuss the consequences of attractive interactions
for the collision mechanisms, which is described by (2)a n d
(4). To account for the decrease in the rate constant at high




















Clearly, for weak loading (i   m and j   m) the original
ﬁrst-order model leading to the exponential behavior in (8)
is recovered. For large loading of either donor or acceptor
liposomes, the transfer rate becomes small. We note that
using (22) does not lead to a set of diﬀerential equations in
terms of only Md(t)a n dMa(t). Here, we do not attempt to
provide an analytical solution to the problem. Instead, we
illustrate its predictions by numerically solving (2)a n d( 4)
with g(i, j)g i v e ni n( 22).
Figure 5 shows the behavior of Md(t)a n dMa(t)a s
function of tK (with K = KcollN/V), derived for m =
100. For simplicity, we have set k = 0w h i c hr e s u l t si n
an equipartitioning of drug molecules between donor and
acceptor liposomes (Md/Nd = Ma/Na = M/N). We start
with Nd = Na = 100 liposomes. The acceptor liposomes
are initially empty whereas each donor liposome contains
initially l drug molecules (out of a maximal number m =
100). Diﬀerent curves in Figure 5 correspond to l = 2( a ) ,
l = 10 (b), l = 50 (c), l = 90 (d), and l = 98 (e). As long as
the drug loading is weak (curves (a) and (b)), the solution is
simply exponential, characterized by Ma/M = 1 − Md/M =
(1 − e−Kt)Na/N (see (8)w i t hk = 0). Here, the kinetics is
independent of the total number of drug molecules M = lNd
(which is why curves (a) and (b) virtually overlap). If the
initial loading of the donor liposomes becomes larger (curve
(c)) the kinetics slows down. Eventually, once the initial
loading approaches its maximal value mNd, the behavior
slows down even more and, in addition, becomes sigmoidal.
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Figure 5:Fractionofdrug moleculescontainedindonorliposomes
(Md(t)/M; upper set of curves) and acceptor liposomes (Ma(t)/M;
lower set of curves) as function of the scaled time Kt.T h ec u r v e s
represent numerical solutions of (2)a n d( 4)w i t h( 22), derived for
k = 0a n dm = 100 with the initial conditions dj(0) = 0f o rj / =l,
dl(0) = 100, aj(0) = 0f o rj>0, a0(0) = 100. Diﬀerent curves
correspond to l = 2( a ) ,l = 10 (b), l = 50 (c),l = 90 (d),and l = 98
(e).
Attractivedrug-druginteractionsslowdowntherelease from
initially highly loaded donor liposomes; at later times (when
the donorliposomes are no longerhighly loaded), therelease
becomes faster. This leads to sigmoidal behavior.
3.3. Extension to a Two-State Model. In the ﬁnal part of
this work, we brieﬂy discuss an extension of our model to
account for two distinct states of the drug molecule inside
each liposome. A simple rationale for the presence of two
distinct states is provided by the bilayer structure of the
liposomes. That is, a drug molecule may preferentially be
bound to either the inner or outer monolayer, having to ﬂip-
ﬂop in order to change the host monolayer. The typical ﬂip-
ﬂop time can be large if the drug has some amphiphilicity
or surface activity instead of being strongly lipophilic [40].
Drug molecules residing in the inner monolayer cannot be
transported directly to another liposome; they ﬁrst have to
migrate to the outer monolayer.
We denote by MI
d and MO
d the number of drug molecules
residing in the inner (DI)a n do u t e r( DO)l e a ﬂ e t so fd o n o r
liposomes, respectively. Similarly, MI
a and MO
a refer to the
number of drug molecules residing in the inner (AI)a n d
outer (AO) leaﬂets of acceptor liposomes. The reaction
scheme in (10) can then be generalized to account for the

















2 are the two rate constants corresponding
to the transfer of drugs between the two leaﬂets of the
donor liposomes (and similarly for Ka
1 and Ka
2 referring8 Journal of Drug Delivery
to the acceptor liposomes). The rate constants K1 = (1 −
kNd/M)KNa/N and K2 = (1 + kNa/M)KNd/N are identical
to those for the single-state model, where K i sg i v e ni n( 19).
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In the limit of a symmetric lipid bilayer, the two rate
constants for ﬂip-ﬂop of a drug molecule from the inner
to the outer leaf and from the outer to the inner leaf are
identical (we note that the two leaﬂets of a liposomal bilayer
are not strictly equivalent which, in a more reﬁned model,
would entail two diﬀerent rate constants for ﬂip-ﬂop; this
dependence on liposome curvature is neglected here). If we
assume furthermore that donor and acceptor liposomes are






















































depend on only two parameters, the rate constants K and G.
If we assume all drug molecules initially reside in the donor
liposomes, the initial conditions are MO
d (t = 0) = MI
d(t =
0) = M/2, and MO
a (t = 0) = MI
a(t = 0) = 0, where M is the
total number of drug molecules in the system. The solution


















































The solution is thus a combination of exponential decays
with corresponding eﬀective rate constants ω1 and ω2.S u c h
biexponential behavior has been observed for the sponta-
neous transfer of certain lipids between phosphatidylcholine
vesicles [41] and also for the release behavior of an imidazole
derivate from liposomes [42]. The eﬀective rate constants ω1
and ω2 can be calculated from G and K through
2G+K = ω1 + ω2,4 G2 +K2 = (ω2 − ω1)
2. (27)
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a(t)areplotted according to(26)forG/K = 1/10andNa/N =
Nd/N = 0.5 .T h eb r o k e nl i n e ss h o wt h eb i e x p o n e n t i a lb e h a v i o r so f
the sums Md = M
O
d + MI
d and Ma = MO
a + MI
a.T h et i m ei sp l o t t e d
in units of the inverse rate constant K.N o t ea l s oω1 = 1.11K and
ω2 = 0.09K are the eﬀective rate constants for the decay.
Hence, a measurement of ω1 and ω2 could be used to obtain





a(t), Ma(t), Md(t), calculated for
G/K = 1/10 and Na/N = Nd/N = 0.5. All drug molecules
are initially distributed equally among the two leaﬂets of
the donor liposomes. Release of drug molecules from the
outer leaf of the donor liposomes is fast (K = 10G), the
slow process is the ﬂip-ﬂop of drug molecules between the
two leaﬂets of the liposomes. Hence, at intermediate times,
say at t = 3/K, the outer leaﬂets have almost reached
their equilibrium values whereas the inner layers remain still
fairly close to their initial values. After reaching thermal
equilibrium (t →∞ ), half of all drug molecules have
migrated to the acceptor liposomes. Clearly, the presence
of the two diﬀerent rate constants (K and G)l e a d st ot h e
biexponential behavior of Md and Ma in Figure 6.
We brieﬂy discuss two limiting cases for (26). First, for
G = 0 the ﬂip-ﬂop of drug molecules between the inner
and outer leaves is inﬁnitely slow, implying MI
d(t) = M/2,
MI
a(t) = 0, MO
a (t) = M/2−MO
d (t) = (1−e−Kt)(MNa)/(2N).
In this case, we recover the kinetics of (8), yet with only
M/2( i n s t e a do fM) drug molecules participating in the
transfer and identical donor and acceptor liposomes (k =
0). Second, for G →∞ ﬂip-ﬂop becomes inﬁnitely fast
and (26)r e a dMI
a(t) = MO
a (t) = M/2 − MI
d(t) = M/2 −
MO
d (t) = (1 − e−Kt/2)(MNa)/(2N). Because 50% of the
drug molecules reside in the inner leaﬂets, they do not
contributetotheouter-leaﬂet-concentration-diﬀerencesthat
drive the transfer kinetics. Hence, the apparent rate constant
is reduced from K to K/2.Journal of Drug Delivery 9
4.Conclusions
In this work, we have presented a detailed model for the
transfer kinetics of poorly water-soluble drug molecules
between liposomal carrier systems. Apart from liposomes,
the scope of the model includes other types of small and
mobile pharmaceutical nanocarriers, such as micelles, col-
loids, and nanoparticles. Starting from a microscopic distri-
bution function of drug molecules among donor and accep-
tor liposomes, we have speciﬁed the conditions that lead
to an apparent ﬁrst-order kinetic behavior. These include
low drug loading of the liposomes, strict proportionality
of all rate constants to drug concentrations, no aggregation
phenomenaofdrugswithin liposomes, and no overlap ofthe
intraliposomal ﬂip-ﬂop kinetics. Systems that do not fulﬁll
these conditions do not, generally, exhibit an apparent ﬁrst-
order kinetics. Instead the behavior may become biexponen-
tial or sigmoidal. High drug loading may preserve the ﬁrst
order kinetics but with increased apparent rate constant.
An optimal drug delivery system should keep the drug
load on the way to the target and release it only after arrival
at the target. Understanding the kinetics and mechanisms
of drug release from liposomal (and other) nanocarriers is
thus a prerequisite to systematically improving drug delivery
systems.
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